What is Estrella Immunopharma Inc.?
, a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 14.11M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.